Feed CYBN
CY

Cybin Inc.

CYBN · AMEX

$8.28 +1.22% (+$0.10)
Piotroski F-Score Weak
0/9
Valuation
-
N/A
P/E N/A
EV/EBITDA N/A
P/S N/A
Growth
-
N/A
EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A
Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
-
N/A
ROIC N/A
ROE N/A
ROA N/A
Debt
-
N/A
Debt/Equity N/A
Current ratio N/A
Int. coverage N/A
Stability
100 /100
Stable
Beta 0.79x
Rev. volatility N/A
EPS volatility N/A

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o CYBN
Online

O podjetju

Cybin Inc. (CYBN) is a biotechnology company specializing in the development of therapeutic therapies based on psychedelic compounds for the treatment of various mental disorders. The company focuses on developing medications that utilize psychedelic substances such as psilocybin to support the treatment of conditions like depression, anxiety disorders, and post-traumatic stress disorder. Cybin Inc. is engaged in clinical studies and research to provide new treatment options for patients suffering from mental illnesses. With the growing interest in alternative therapeutic approaches in the field of mental health, Cybin Inc. has the potential for sustained growth. Cybin Inc. (CYBN) shares might be an interesting choice for investors seeking involvement in the biotechnology and therapeutic therapies based on psychedelic compounds industry.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Eric So

Employees

50

Headquarters

Toronto

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.